Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland

201135 citationsJournal Articlehybrid Open Access

Authors

Thomas D. Szucs · University of Basel

Reto W. Kressig · University of Basel

Manto Papageorgiou

Werner Kempf · University Hospital of Zurich

Jean‐Pierre Michel · University of Geneva

Anton Fendl · Sanofi (Switzerland)

Xavier Bresse · Sanofi (France)

Abstract

The model predicts clinical and economic benefits of vaccination in the form of fewer HZ and PHN cases and reductions in healthcare resource use. ICERs were within the commonly accepted thresholds in Switzerland, indicating that a HZ vaccination program would be considered a cost-effective strategy in the Swiss setting.

Topics & Keywords

Herpesvirus Infections and Treatments Hepatitis Viruses Studies and Epidemiology Virology and Viral Diseases

Publication Details

Published in: Human Vaccines

Volume 7, Issue 7, pp. 749-756

DOI: 10.4161/hv.7.7.15573

Field-Weighted Citation Impact: 2.00

Command Palette

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland

Authors

Abstract

Topics & Keywords

Publication Details